slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 231,331-231,360
Pages 10,126
Rows per page 30
Component
231,331-231,360 of 303,780
03
Genelux | Investor Presentation Deck | 37 slidesGenelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
06
Uses a process flow diagram to illustrate the transition from cold to hot tumor states.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
07
The central diagram illustrates the biological mechanism of action, contrasting 'Absence of Effector T Cells' (Platinum resistant) with 'Presence of Effector T Cells' (Platinum sensitive).Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
08
Uses a pyramid/staircase diagram to show progression of clinical advantages.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
09
The slide uses a document-style callout for key takeaways and a vertical list of icons for clinical results.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
11
Data presented in a table format comparing patient cohorts against clinical metrics.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
12
Waterfall plot and spider plot showing patient-level clinical outcomes.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
14
Includes a comparison table of historical data vs ELAHARE and a specific VIRO-15 clinical outcome table.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
16
The slide outlines a clinical trial protocol, specifically a randomized open-label study comparing an experimental arm to an active comparator arm.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
17
Includes Kaplan-Meier survival curves and patient cohort descriptions for two separate study groups.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
18
Includes specific patient case reports with RECIST criteria and biomarker data.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
19
Includes a bio for Benny Li, CEO of Newsoara.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
20
Genelux | Investor Presentation Deck | 37 slidesGenelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
21
The slide highlights the synergy between two existing therapies (TVI and Olvi-Vec) to create a new modality.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
22
The slide uses a hub-and-spoke style layout to categorize strategic pillars.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
23
The slide uses a combination of a bulleted list and a hub-and-spoke style visual representation of facility locations.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
24
The slide categorizes the platform's capabilities into therapeutic genes, immune modularity, and therapeutic antibodies.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
25
The slide highlights key competitive moats including patent counts, freedom to operate, and regulatory protections.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
27
Includes specific footnotes regarding market close date, cash reporting date, and PIPE commitment details.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
28
The slide uses a dual-track visual: a list for past milestones and two curved arrows for future milestones.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
29
Genelux | Investor Presentation Deck | 37 slidesGenelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
30
Genelux | Investor Presentation Deck | 37 slidesGenelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
31
The slide lists key clinical advisors, highlighting their leadership roles in major oncology organizations and clinical trials.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
34
Includes patient-specific histological evidence (Pt.#15A-01 and Pt.#15A-11) demonstrating the mechanism of action.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
35
The slide uses histology images and HALO infiltration histograms to demonstrate the mechanism of action and clinical efficacy.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
36
The slide uses a combination of clinical timeline, patient history, and immunological data (ELISPOT) to correlate T-cell response with clinical outcome.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
37
The slide uses clinical study data (VIRO-15, NCT01443260) to validate the mechanism of action.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
02
GMS | Results Presentation Deck | 20 slidesGMS | Results Presentation Deck | 20 slides · GMS
Conference presentation Investor relations 1 hit
03
Includes a table of net sales by product, a pie chart of sales mix, and bulleted financial highlights.GMS | Results Presentation Deck | 20 slides · GMS
Conference presentation Investor relations 1 hit
04
GMS | Results Presentation Deck | 20 slidesGMS | Results Presentation Deck | 20 slides · GMS
Conference presentation Investor relations 1 hit